CHICAGO--(BUSINESS WIRE)--CytoCore Inc. (OTCBB:CYCR), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, today announced that Baylor University, University of Pittsburgh and University of Cincinnati are beginning to participate as new sites in CytoCore’s current e2 Collector(TM) clinical trial. The current collector utilizes the same technology as previous versions. The improvement is “push button” convenience speeding the test and eliminating user caused sampling errors.
